Support the Troops: Invest in Legal Cannabis!
How to Make Money and Save Lives at the Same Time
It’s not just about the money.
I know, this is not typically something you’d expect to read from an investment analyst, so let me explain …
A few years ago, I started writing about investment opportunities in the legal cannabis space. As a result, I was accused by many of compromising my ethics in an attempt to make a quick buck. But nothing could be further from the truth.
Yes, one of the reasons I invest in the cannabis space is because it’s insanely profitable. And I make no apologies for this, nor should any other right-minded capitalist who enjoys the spoils of free markets and the good fortune to create wealth and prosperity.
The truth is, at the moment, there is no greater investment opportunity than legal cannabis. And I have dozens of double- and triple-digit winners in my portfolio to back up this claim. Some of my most profitable cannabis investments right now include a 501{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} gain on Canopy Growth Corporation (TSX: CGC), a 373{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} gain on Aphria, Inc. (TSX-V: APH), and a 567{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} gain on OrganiGram (TSX-V: OGI). And there are plenty more to come, too.
But while few things make me smile more than watching my brokerage account grow, this is not the onlyreason to invest in the legal cannabis market.
Three Reasons to Invest in Legal Cannabis
Aside from the massive profit potential, there are three other reasons you should be investing in legal cannabis right now:
- Legalization helps slow the war on drugs, which has been one of the most violent and costliest wars in recorded history. More than $1 trillion has already been spent on this war, and it’s put millions of folks — particularly the poor — in early graves.
- Legalization helps build local economies, which, in this day and age, is something we need to embrace, not shun.
- Legalization on the medical side allows millions of Americans to treat illness when other “legal” pharmaceuticals have failed. How anyone could look at a young child with severe epilepsy and deny that child a medical cannabis therapy that’s proved to work is beyond me.
Of course, it’s not just kids with epilepsy that have benefited from cannabis.
Support the Troops
Last year, while attending a legal cannabis conference in New York City, I met a man named Sean Kiernan.
Kiernan is the co-founder of a group called Weed for Warriors. It’s an advocacy group that works to provide access to medical cannabis for military veterans suffering from PTSD.
Now, the fact that a military veteran — someone who has risked his or her life for this country — can be denied medicine to treat PTSD is despicable. Especially when you look at some pretty unsettling statistics.
The suicide rate for veterans is extremely high. Every year, about 8,000 veterans commit suicide. That means that since we first invaded Iraq back in 1991, more than 200,000 U.S. veterans have taken their own lives. And understand, this is a group that makes up just 7{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of the U.S. population but represents 20{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of the national suicide rate. And that’s assuming these numbers are accurate — which they are not.
Truth is, this data has only been collected from 21 states and only accounts for the vets who have been seen by the Veterans Affairs Administration. Sadly, those numbers are likely considerably higher. And that’s an absolute travesty. Especially when you consider that many of these deaths could’ve been avoided.
You see, there’s a significant amount of evidence that indicates cannabis can effectively treat the symptoms of PTSD. One study in particular, conducted by the scientific journal Drug Testing and Analysis found that cannabis could “dampen the strength or emotional impact of traumatic memories through synergistic mechanisms that might make it easier for people with PTSD to rest or sleep and to feel less anxious and less involved with flashback memories.”
Of course, to get similar conclusions, one could also simply ask any veteran who uses cannabis to treat the effects of PTSD.
Some do it legally, assuming they live in states where cannabis has been legalized for the treatment of PTSD, and some do it illegally, since the very country that sent them off to war won’t allow them to medicate as they see fit.
Think about that for a moment.
These folks put their lives on the line for us every single day. They’re not paid large sums of money to do this either. These are honorable men and women who not only deserve to be treated with the respect they’ve earned, but also deserve the right to use any medication they choose to keep them safe and healthy.
How any lawmaker in this country could deny a United States veteran medication is beyond me. As far as I’m concerned, this is nothing short of a human rights violation.
Regular People have the Power to do Great Things
Most of us are just regular people.
We’re not billionaires with loads of influence in Washington. We’re not lawmakers, judges, or high-profile celebrities. But that doesn’t mean we can’t do our part to keep our vets healthy and safe.
You see, as investors, collectively, we have an enormous amount of power. Every day, billions of dollars worth of public equities are bought and sold on the open market. And I’m not talking about fancy algorithms created by investment banks and hedge funds. I’m talking about regular, retail investors. Folks that have online trading accounts and are happy with year-end returns of eight to ten percent.
Now imagine if all these investors decided to allocate just one percent of their portfolios to stocks that represent companies that are making it possible for our veterans to get the relief many of them need by providing medical-grade cannabis.
While the U.S. government may not be willing to do right by the very people that protect our democracy, we can override that decision through our collective purchasing power, which will result in strengthening the cannabis industry thereby making it harder and harder for the government to continue its prohibition against something that, quite frankly, never should’ve been prohibited in the first place.
Of course, I’m not suggesting you run out and buy a bunch of random cannabis stocks. Especially those listed in the U.S., which, for the most part, are garbage. Investing in a stock that’s not going to make you any money makes no sense. Particularly because such a stock is likely issued by a company that’s not going to be around very long. And that’s not going to help anyone.
But there are exceptions. Take Innovative Industrial Properties (NYSE: IIPR) for instance. This is a REIT that acquires specialized industrial real estate assets that are used for growing medical-use cannabis and operated by state-licensed growers. Just a few weeks ago, IIPR closed its first transaction with PharmaCann, a cultivator of medical-grade cannabis. This transaction alone guarantees the company an initial base rent of $319,580 per month. That ain’t chump change.
It should also be noted that the company’s executive chairman is the guy who co-founded BioMed Realty Trust, which was sold to Blackstone last year for $8 billion. These guys aren’t amateurs.
Of course, if you’d rather focus on actual cannabis producers, one of your best bets might be with Emblem Corp. (TSX-V: EMC).
While this is a Canadian cannabis producer, management is actively developing advanced cannabis formulations designed to help folks with PTSD. This research alone could prove to be incredibly valuable to other producers in the U.S. that are currently providing cannabis for vets with PTSD.
Here’s the bottom line: As a legal cannabis investor, we can not only make a lot of money, but we can also help facilitate a movement that can help our veterans get the medication they need… a medication that could help these folks live normal lives… a medication that could quite possibly decrease the number of veterans that commit suicide, too.
And that, my friend, is an honorable investment.
Source (Wealth Daily)
- Published in Blog, Medical Marijuana, Namaste Technologies, Tetra Bio Pharma
Tetra Bio-Pharma (TBP.C) Provides USA Regulatory Update for its Cannabis Inhalation Product
Tetra Bio-Pharma Provides USA Regulatory Update for its Cannabis Inhalation Product PPP001
– Momentum Public Relations –
Press Release: November 23, 2016
PhytoPain Pharma Inc. (“PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP) (CSE:TBP.CN) (OTC PINK:GRPOF), is a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that the development of its smoked marijuana prescription drug is on schedule.
The Company confirmed that, on November 8, 2016, it received a letter from the Office of Combination Products stating that the USA Food and Drug Administration (“FDA“) had completed its review of the request for designation for the marijuana prescription drug and titanium pipe kit. The FDA confirmed that the product is a combination product, and assigned it to the Center for Drug Evaluation and Research (“CDER“) as the lead agency center for premarket review and regulation based on FDA’s determination of the marijuana product’s primary mode of action.
The Company previously announced that it received a pre-IND (Investigational New Drug) acknowledgement and meeting request granted letter from the US FDA. This week, the company is submitting the information package required by FDA for the Type B pre-IND meeting in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products, Center for Drug Evaluation and Research. According to Dr. G. Chamberland, Chief Science Officer, “As per FDA policies, the pre-IND information package is submitted to obtain guidance from FDA on the product development and marketing requirements for the smoked marijuana prescription drug combination product”. Dr. Chamberland further commented that this regulatory filing is part of PPP’s dedication to the commercialization of marijuana as a prescription controlled drug and the corporation’s plan to seek reimbursement by insurers for patients.
The Company has been working with Algorithme Pharma, an Altasciences company, for the conduct of its Phase I clinical trial in healthy human subjects. PPP is using the services of Algorithme Pharma based on its experience and expertise in the conduct of clinical trials for the pharmaceutical industry. Later this week the project team will be submitting the Phase I clinical protocol, and related documents, to the Institutional Review Board for review. If approved, Algorithme Pharma will subsequently submit the Clinical Trial Application to the Therapeutic Products Directorate of Health Canada for approval. In parallel, Algorithme Pharma will submit an application for exemption under section 56 of the Controlled Drugs and Substances Act for its planned research on healthy subjects.
The Company stated that, subsequent to a request for classification to the Medical Devices Bureau, Health Canada, the PPP001-titanium pipe that will be used in the clinical trial is a Class I medical device. Dr. Chamberland commented: “As a Class I medical device, the PPP001-titanium pipe does not require approval for use in the clinical trial”.
About PPP001-kit product
PPP001-kit product will be sold as two separate products packaged together in a single package and is comprised of the drug PPP001 and the device PPP001-titanium pipe. The drug component and device component will be linked together by the labelling of each component.
The product PPP001-kit, once approved, could be sold in pharmacies containing the prescription controlled drug PPP001, in a blister pack, and the PPP-titanium pipe device that will be used to generate the smoke to deliver the active ingredients by inhalation.
PPP001 drug pellet blisters and a fully assembled PPP-titanium pipe for combustion and inhalation of the generated smoke are required for therapy with PPP001 and are provided in the PPP001-kit.
Each blister of PPP001 drug pellet contains marijuana with a standardized amount of delta-9-tetrahydrocannibinol and cannibidiol. A single PPP001 drug pellet is pushed out of the blister by the patient and inserted into the PPP-titanium pipe.
In Other News:
The Company has received $227,738 in exercised warrants for November 2016.
- Published in Bio technology, News Home, Tetra Bio Pharma
Namaste (N:CSE) Expands Product Portfolio in Advance of US Elections
Namaste Expands Product Portfolio in Advance of US Elections
– Momentum Public Relations –
Press Release: November 3, 2016
Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N)(FRANKFURT:M5BQ) is pleased to announce that the Company has secured new agreements with manufacturers of indoor growing equipment. These product lines will be added to Namaste’s e-commerce portals and complement the Company’s existing portfolio of vaporizers, pipes, papers and other accessories. This new product portfolio also represents a further monetization of Namaste’s customer list of approximately 250 thousand names.
US Elections
Currently, cannabis is legal for medical use in 25 states and recreational use in four states. Next week, the US will have three states voting on the legalization of medical use (Florida, Arkansas, and North Dakota) and five states voting on the legalization of recreational use of cannabis (California, Massachusetts, Arizona, Nevada, and Maine). Should all five states vote in favor of recreational marijuana, the US could have upwards of 75 million people living in states where the recreational consumption of cannabis will be legal. This represents approximately 23{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of the total US population and is anticipated to advance the potential for legalization in additional states. In the US, support for the legalization of cannabis reached an all-time high of 57{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} in favor. Namaste’s product portfolio is ideally positioned to capitalize on these potential developments in the US.
Agreement Details
Namaste has entered into agreements with Gorilla Grow Tent Inc., SuperCloset Inc. and Kind LED Grow Lights, all leading manufacturers of the most advanced growing equipment available on the market. Namaste will initially market each of the manufacturers’ products in the US and Canada, and will receive wholesale rates on product sales. It is anticipated after the initial launch, Namaste will launch each of these brands into the twenty international markets Nasmaste currently serves.
Management Commentary
Sean Dollinger, President and CEO of Namaste, comments: “The markets for our current and new products are expanding considerably. With the acquisition of VaporSeller and URT1, we have given ourselves a substantial position in the US market which now represents 74{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of our customer base. We view the upcoming election in the US as a key catalyst for our company and will continue to focus our efforts on expanding our brands in the US, which is the largest market for our products globally.”
About Gorilla Grow Tent Inc.
Gorilla Grow Tents are professionally designed grow tents that are ideal for experts and perfect for beginners and set the standard for quality and durability. Each grow tent is built with stable reinforced materials and are the strongest and safest materials available. Gorilla Grow tents have no plastic and feature a proprietary diamond reflection technology for best yield. Gorilla Grow Tents also feature a patent pending adjustable height extension kit that gives you the ability to increase your growing height from 7′ to 8′ or even 9′ tall.
About SuperCloset Inc.
Founded by Kip Anderson in 2002, SuperCloset, also known as SuperPonics, is accredited by the Better Business Bureau and maintains a perfect A+ rating, surpassing any other company in the hydroponics industry. SuperCloset is known as the leading manufacturer of Automated Superponics Systems and Grow Boxes in the world. Based in beautiful San Francisco, California, the company is in the perfect environment for combining innovative and imaginative ideologies with progressive methods of harvesting local, sustainable and organic products.
About Kind LED Grow Lights
Kind LED Grow Lights are the industry leader in indoor LED grow lights. Kind LED consulted with hundreds of professional hydroponic and soil growers to rigorously research and develop their cutting edge LED indoor grow light technology that has since revolutionized the indoor growing industry. Kind LED is widely considered the best indoor LED grow light on the market today. Kind LED Grow Lights are comprised of high powered 5 and/or 3 Watt Light Emitting Diodes featuring a proprietary intensified 12 band spectrum, including infrared and UV diodes designed for both vegetative and flowering stages of growth.
About Namaste Technologies Inc.
Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.
- Published in Namaste Technologies, News Home
Aurora (ACB:CSE) Continues Accelerated Growth
Aurora Continues Accelerated Growth
– Momentum Public Relations – Feb. 2, 2016
Aurora Cannabis Inc. (“Aurora” or the “Company”) (CSE:ACB)(OTCQB:ACBFF)(FRANKFURT:21P) (WKN: A1C4WM) is pleased to announce that its wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., a producer and distributor of medicinal cannabis pursuant to the Marihuana for Medical Purposes Regulations (“MMPR”), has registered hundreds of fully authorized medical cannabis clients, crop yields have proven to be 100 percent more productive than forecasted, and the strain selection will expand rapidly this month.
Aurora’s recent crop yielded 1.36 grams per watt, or 1.4 kilograms (3.08 pounds) per light. The facility, with 55,200 square feet of expandable licensed production space, will be running at full capacity by spring 2016, with a demonstrated capability of producing over 7,000 kg of dried cannabis annually.
Furthermore, the Company recently launched its revamped website at www.AuroraMJ.com with a streamlined registration process and user-friendly patient and physician portals. Registrations began January 4th, 2016, with all Aurora strains being priced at $8 per gram, as well as a $5 per gram compassionate pricing standard across all strains.
Three-hundred and ten people became a part of Aurora’s ‘Founding 420’ in the month of January. Each member of the Founding 420 represents one of the Company’s first four-hundred and twenty clients. This bestows upon each member a number of benefits, including a welcome package with an Aurora-branded DaVinci Ascent portable vaporizer, a premium Aurora grinder, free cross-country shipping, and $50 in Aurora credit. In return, Aurora will be asking for detailed feedback with respect to the product, the service, the delivery, our brand and other key metrics.
Neil Belot, Chief Brand Officer, comments, “People have been eagerly waiting to experience the Aurora Standard, and the response from the community has been fantastic. The Founding 420 welcome package has been a big hit and everyone is wondering what we are up to for our next campaign; here is a hint – 710.”
Over the next several months, one of Aurora’s future strains availabile is poised to make global headlines. Facility Director, Joel Fuzat, explains why:
“In February 2016, Aurora intends to begin selling its flagship CBD cannabis strain. This groundbreaking development represents new heights in the field of medicinal marijuana in Canada. Our CBD-rich strain tested at over 25{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} CBD and just 1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} THC by an independent third-party laboratory during the qualification run, which would make this the highest percentage CBD flower in Canada by a significant margin.”
Cannabidiol, also known as CBD, is a non-pyschoactive cannabinoid. To date, according to various medical studies it has shown promise as a treatment for chronic pain, seizures, epilepsy, multiple, sclerosis, anxiety, different forms of inflammation, and regulation of immune system functioning amongst others. Further studies are underway to explore its promise as an inhibitor of cancer cell growth.
Additionally, Aurora’s application for a Section 56 exemption to produce cannabis derivatives, such as CBD oil products, has been submitted to Health Canada for approval. In anticipation of the introduction of this new suite of products, Mr. Bryan Pyle, an expert in chromatographic separation and extraction, has been added to the Aurora team.
Aurora CEO, Terry Booth, says, “We are thrilled to have Bryan join us. His experience in high value plant metabolites is invaluable. Bryan will help to ensure standardization and consistency in all our extract-based products. The Aurora Standard continues to resonate with people and raise the bar for the industry as a whole.”
Terry Booth also commented, “Now that we shored up our cash position, we can execute on a number of key initiatives that will swiftly strengthen market share and likely bring us to profitability in the shortest time frame accomplished by any publicly traded Licensed Producer in the MMPR industry to date.”
About Aurora Cannabis Inc.
Aurora’s wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical marijuana pursuant to the Marihuana for Medical Purposes Regulations and operates a 55,200 square foot expandable state-of-the-art production facility in Alberta, Canada. Aurora’s wholly-owned subsidiary, Australis Capital Inc., is an active participant in the U.S. Cannabis market. Aurora is trading on the Canadian Securities Exchange under the trading symbol “ACB”.
- Published in Aurora Cannabis, News Home
The MMPR Investments Report: Organigram (OGI:V)
The medical marijuana space in Canada has been crazy for the last year.
From the sudden emergence of a corporate medicinal cannabis supply system to court cases allowing formerly registered users to continue growing their own product, to the crazy profligation of unregulated dispensaries in Vancouver while other cities shut them down as soon as they appear, the mining-to-marijuana rush, the crazy share price spikes and crashes, the suited brokers shoving through barbed wire fences to do deals with motorcycle club employees, the boardrooms with baggies of samples being passed around… nobody could have foreseen the madness.
But out of madness, eventually, comes sanity. And the Canadian weedspace right now is verging on the sane.
Gone are many of the early share price rockets. Companies like Green and Hill, and Growlife, and Enertopia, and Creative Edge Nutrition, which had market caps as high as when they launched, now scrape bottom. The ticker symbol plays like BUD and THC are nowhere to be seen. And investors that, formerly, played all day, bouncing their cash from play to play depending on what was being promoted, are now butthurt, poorer, and looking for where to go next.
That’s the bottom end.
At the top, some serious wheels are turning. I’ve looked deep into the soul of many of these companies and I like what I see. Canadian medical marijuana is a mess of bureaucratic regulations, to be sure, but that torturous process has effectively allowed the market to be filtered through a sieve that has left only the high quality, the well-funded, the professionally run and the well supported companies standing.
Companies like Bedrocan, the Canadian subsidiary of a Dutch parent that has the monopoly on European medical marijuana and has earned $1m in revenue just reselling imported product from its parent. And Tweed, which two licensed facilities and a big war chest, the first mover in the market that stands tall on its effective marketing campaign and US investor base penetration. And Mettrum, a new player that keeps it cards close to its chest while it quietly connects registered patients to its product. And Supreme, which is marching towards its license with a plan to grow medical marijuana in a massive Ontario based facility, and sell it on the cheap to feed the low end of the market.
These are all fine companies. There are others, earlier in their licensing process, that may add to the roster. But there’s one that, right now, to me, has demonstrated it stands tall.
That company is Organigram.
You’ll find it in the Canadian markets under the ticker V.OGI. In the US, it’s OGRMF.
Why do I like this company? How much do I like this company?
Let’s get into that.
Organigram is not selling more weed than anyone else. It’s not got more name recognition than anyone else. It’s not sitting on a billion square feet of growing space. But it has something REALLY important in Canada, and North America proper.
It has a deal.
That deal is with Trauma Healing Centres (or THC), a group that is opening a series of clinics across Canada aimed at treating people with post-traumatic stress disorder. That means, largely, military veterans and first responders.
The deal promises to bring Organigram as much as $22m over the first two years, and to expand outward from that. But while that’s nice, it’s not the most important thing.
The deal also promises to give Organigram a bankable off-take arrangement upon which it can plan ahead. Instead of fighting for every patient, the THC group will bring the patients to them. But that’s not the most important thing.
The deal will embrace Organigram’s certified organic product (something no other company has), and will take advantage of the company’s truly bilingual structure (something, again, no other company has, and which gifts the company Quebec as a virtual monopoly).But, again, not the most important thing.
The important thing is veterans in Canada have government-backed health insurance, and medical marijuana is an accepted treatment for PTSD.
This means Organigram has a deal that, as a first in North America, will be insurance-backed, to serve a large segment of the population exclusively.
Anxiety disorders, or which PTSD is one of the largest segments, cost the US health system $42.3 billion annually, according to the Sidran Institute. Around half of that is spent on drugs, and those drugs are significantly more expensive – and less effective – and have more side effects – than medicinal cannabis.
Currently, Health Canada puts the potential market for medical marijuana at $1.3b per year in 2022. So if Organigram can be the go-to place for Canadian veterans and first responders to turn to for their PTSD relief, the market radically dwarfs the expected registered medical marijuana user for all other ailments.
This won’t happen tomorrow. It won’t happen next month. But when it happens, when the healing centres open and the veterans groups, which are behind THC, start moving their brothers into that system, Organigram won’t have time to scratch itself for all the business it’ll be handling.
And that’s why the company, right now, is working feverishly to expand. All the money it has raised in previous months, all of it is going to expansion of its present facility – something it can do because it just purchased the building next door and worked with the municipality to merge the two properties into one address. No need for a new MMPR!
I own Organigram stock. I’m not selling. I’m going to have to make that disclosure every time I write about this company for a long time to come because I have no plans to cash in my stake. I’m waiting for dividends, and I’m very happy in my belief dividends will one day flow hard.
There are several great investment options in medical marijuana in Canada. You should seriously consider them and invest where you think your money will be safest and most productive.
For me, that’s Organigram. V.OGI. Get in.
Written by: Chris Parry
NOTE: The author of this report has been paid for its production and dissemination and owns Organigram stock. Please do your own due diligence before making any investment and speak to a licensed professional for investment advice.
- Published in Blog
OrganiGram ships first medical marijuana orders
ORGANIGRAM PASSES PRODUCT TESTING AND SHIPS MEDICAL MARIJUANA TO CUSTOMERS
OrganiGram Holdings Inc. has shipped its first orders of medical marijuana to customers.
The product being shipped was sent to RPC Laboratory to undergo product testing as per Health Canada guidelines. The company has received the results of said testing that confirm the product to be in conformance with the Health Canada marijuana for medical purposes regulations (MMPR).
Chief executive officer Denis Arsenault states: “We are extremely pleased to have passed testing and shipped product to our first customers. The fact that we were able to produce product that passed testing without the process of irradiation (cold pasteurization) confirms the high quality of our team, facility and validated the benefits of our organic growing process.”
d
- Published in Medical Marijuana
Cannabis Oil Cures Infant of Cancer, Dissolves Inoperable Tumor
Guest Writer for Wake Up World
According to Dr. William Courtney, the western medical mind has a very hard if not impossible time trying to understand the diverse actions of Cannabidiol.
A Doctor of Medicine with extensive education and experience in microbiology, psychiatry and forensic medicine, Dr. William Courtney explains how his 8 months old patient had a massive centrally-located, inoperable brain tumor. The child’s father pushed for “non-traditional” treatment utilizing cannabis and put cannabinoid oil on the baby’s pacifier twice per day, gradually increasing the dose. Within two months there was a dramatic reduction in the size of the baby’s tumor.
Dr. Courtney pointed out that the success of the cannabis approach means that “this child… is not going to have the long-term side effects that would come from a very high dose of chemotherapy or radiation”.
Cannabis Cures Inoperable Tumor
While 10,000 year old cultural practices involve drying then heating cannabis to effect a nearly complete decarboxylation of THC-Acid into THC, the creation of massive amounts of THC is compounded by the introduction of a psychoactive side effect that has a 10 mg dose limitation secondary to CB1 receptor stimulation.
Research conducted in Bethesda Maryland led to Patent 6,630,507 held by the United States of America since 2003 that teaches that the lack of psycho-activity in CBD allows doses that are 100-200 times greater than the tolerable dose of THC. The articulated “effective oral human dosage schedule is 20 mg / kg body weight” requires a considerable amount of cannabis. The simplest approach is to consume the trichrome-laden fully-mature flower along with the 80-day leaf. Patient responses have exceeded any expectations.
Historically, dietary use of the entire raw cannabis plant brings us back in line with 34 million years of cannabis evolution. Lipid messenger molecules preceded cannabis by billions of years. The 4 billion year old development of lipid messenger molecules not only regulated resource management in the most primitive life forms, but were central in the earliest autocrine and paracrine modulation of cellular function. I believe autocrine cross talk was the necessary precedent to symbiotic, then multi-cellular life forms. Tissue specific or paracrine cluster regulation is the domain of the lipid messenger molecules and is the path to comprehending the incredible diversity of function that are only now beginning to be understood. While our perception / publication of these physiologic properties are new, the phenomenal beneficial affects were there yesterday, last year, if not hundreds of millions to billions of years ago.
Researchers have now found that the compound, called cannabidiol, has the ability to ‘switch off’ the gene responsible for metastasis in an aggressive form of cancer. Importantly, this substance does not produce the psychoactive properties of the cannabis plant.
Cannabinoids can prevent cancer, reduce heart attacks by 66{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} and insulin dependent diabetes by 58{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce}. Dr. Courtney recommends drinking 4 – 8 ounces of raw flower and leaf juice from any Hemp plant, 5 mg of Cannabidiol (CBD) per kg of body weight, a salad of Hemp seed sprouts and 50 mg of THC taken in 5 daily doses.
Learn more: 5 Diseases Proven To Respond Better To Cannabis Than Prescription Drugs
“If you heat the plant, you will decarboxylate THC-acid and you will get high, you”ll get your 10 mg. If you don’t heat it, you can go up to five or six hundred milligrams & use it as a Dietary Cannabis… and push it up to the Anti-oxidant and Neuro-protective levels which come into play at hundreds of milligrams”, stated Dr. William Courtney.
“The Hemp plant is actually an excellent plant because the THC content can be low, that’s if you’re treating a condition for which appears CBD food supplement is in order… The plants we’re using in Luxembourg have only 1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} CBD, a 1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} CBD plant is providing you with 19 times more CBD per pound than Oranges provide you of vitamin C. A 1{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} is an excellent source, you can make tremendous concentrates you can eat the plant raw – and the absence of the THC – you can heat Hemp, which you can’t do with other strains because the THC acid comes out and you end up with a psycho-toxic substance”, says Dr. Courtney.
27th July 2014
By Marco Torres
- Published in Medical Marijuana
New Research Shows How Marijuana Compound Can Reduce Tumor Growth In Cancer Patients
Scientists have long known that compounds derived from marijuana have some cancer fighting properties, but a recent discovery demonstrates how exactly one compound may fight tumors.
Published in the Journal of Biological Chemistry, the research reveals two previously unknown “signaling platforms” in cells that allow THC, the psychoactive ingredient in cannabis known for producing the “high” sensation, to shrink some cancerous tumors.
“THC, the major active component of marijuana, has anti-cancer properties,” Dr. Peter McCormick, a researcher from University of East Anglia in England and co-author of the study, said in a statement. “This compound is known to act through a specific family of cell receptors called cannabinoid receptors. However, it was unclear which of these receptors were responsible for the anti-tumor effects of THC.”
When the researchers applied THC to tumors induced in mice using human breast cancer cells, the interaction between two cannabinoid cell receptors — CB2 and GPR55 — were responsible for THC’s anti-tumor benefits.
“Our findings help explain some of the well-known but still poorly understood effects of THC at low and high doses on tumor growth,” McCormick added. He emphasized in an email to The Huffington Post that dosage is critical to outcome, since the wrong protocol can sometimes increase tumor growth, he said.
“So, the ideal would be either the purified THC in an effective dose provided by a health care provider to reduce the known cognitive side effects and still deliver the appropriate reduction in tumor growth, or a synthetic homolog that provides the same effects,” McCormack said. He added that the research team didn’t screen all tumors and that some types may not respond to this treatment if they do not have compatible receptors expressed.
The endocannabinoid (EC) system is a communications network in the brain and body that is involved in a number of physiological processes that affect a person’s feelings, motor skills and memory. The EC system is responsive to the body’s naturally-occurring endocannabinoids as well as the cannabinoids found in marijuana, like THC. And scientists have found that the CB2 receptor specifically is sensitive to the therapeutic properties of marijuana-based compounds.
This isn’t the first time scientists have found that marijuana can be effective at fighting cancer. Previous studies have found that THC cuts tumor growth in lung cancer in half and also prohibited the cancer from spreading. THC has also been shown to induce death in brain cancer cells.
But THC is just one of many cannabinoids found in marijuana. Others, like CBD, a non-toxic, non-psychoactive chemical compound in the cannabis plant, has also shown promise in the battle against cancer. Researchers in California found that CBD could stop metastasis in many kinds of aggressive cancer.
In the United Kingdom, a team of scientists found that six different purified cannabinoids — CBD (Cannabidiol), CBDA (Cannabidiolic acid), CBG (Cannbigerol), CBGA (Cannabigerolic acid), CBGV (Cannabigevarin) and CBGVA (Cannabigevaric acid) — showed a wide range of therapeutic qualities that “target and switch off” pathways that allow cancers to grow.
A number of studies in recent years have demonstrated the medical potential of pot beyond cancer treatment. Purified forms of cannabis has been tied to better blood sugar control, and may help slow the spread of HIV. Legalization of the plant for medical purposes may even lead to lower suicide rates.
Currently, the federal government classifies the plant as one of the “most dangerous” substances alongside heroin and LSD with “no currently accepted medical use.”
McCormack told HuffPost that the researchers are moving toward clinical trials but that it would be at least five years before those would begin.
- Published in Blog
Marijuana, now officially more expensive then gold
Shatter hash and other similar concentrates make up one of the fastest-growing facets of Colorado’s bustling marijuana industry — but shatter, which can be used for dabbing, is also still quite controversial.
Shatter can be dangerous to produce, as many have learned after blowing up their garages or hotel rooms. And it’s also an incredibly potent method of ingesting THC — hardly ideal for the inexperienced pot connoisseur.
Just how popular is shatter?
“At this point gold costs $43.50 a gram,” said Tucker Eldridge, master grower at Nature’s Herbs & Wellness, “and shatter costs $40 a gram off the shelf for medical patients. You add another 30{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} tax to that, and it ends up costing more than gold.”
Shatter can sell recreationally for $60-$90 a gram, Eldridge said in the above video, by Denver Post photographer Joe Amon.
So why do some prefer shatter to flower or edibles?
“If you’re looking for something that’s significantly more potent, has significantly less adulterant plant matter, which is what combusts and produces carcinogens, then shatter hash is going to be more your cup of tea,” Eldridge said. “If you’re not looking for something that’s that potent it can be almost psychoactive.”
- Published in Blog
HIGHMARK ENTERS INTO A NON-BINDING LOI WITH A CORPORATION IN THE FINAL STAGES OF BECOMING A LICENSED PRODUCER OF MARIJUANA
Highmark Marketing Inc. has entered into a non-binding letter of intent with a corporation to acquire 51 per cent of its authorized share capital.
The Corporation is the final stages of their application to Health Canada to become a licensed producer of marijuana under the Marihuana for Medical Purposes Regulations (the “MMPR”). The intended facility is 16,000 square feet and the Corporation has been granted approval from Health Canada to build out the facility (“Ready to Build Letter”). After completing the construction of the facility as per the Ready to Build Letter the Corporation will schedule an inspection by Health Canada, and upon receiving approval the Corporation would then be granted a License to Produce.
Highmark and the Corporation are now negotiating the terms of the long form agreement, and pursuant to the Letter Highmark will issue 30,000 common shares to the Corporation.
The estimated cost of upgrading the facility to comply with the requirements set out in Health Canada’s Ready to Build letter is $2,000,000. The long form agreement will contain a payment schedule whereby Highmark will provide the necessary financing by way of a convertible loan which will convert, at Highmark’s option, into stock of the Corporation that will be equal to 51{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of the total issued and outstanding shares of every class of the Corporation. Highmark intends to fund its commitments under the long form agreement with Corporation by way of an equity financing in the amount of $2,000,000.
The Corporation cannot legally become a producer under the MMPR until it has been granted a license, and it is not known if and when the Corporation will obtain a license. The key milestones to obtaining a license include the completion of upgrades to the facility as per the Ready to Build letter, approval from Health Canada to produce marijuana upon inspection of the facility, and finally approval to distribute the product to patients.
The Corporation has a management team well suited to the production of marijuana. One Co-Founder holds a Master Grower designation and was a producer of marijuana in the U.S.A. under a state sanctioned program, and he has more than 20 years’ experience working in the agricultural sector. Another Co-Founder has been a Health Canada designated grower of marijuana for 3 years, and another key member of the management team holds a Bachelor’s Degree in Economics and has a successful track record of managing a labour force of up to 40 employees.
The Corporation has presented Highmark a comprehensive five-year business plan in which it forecasts to reach profitability in the second year of operations after receiving Health Canada approval to become Licensed Producer. In that second year of operations, the Corporation is planning on sales of up to $472,000 per month, and obtaining $4,720,000 in annual sales, with a corresponding net income of $2,225,000.
Highmark intends on providing new information about the Corporation, and its assets when Due Dilligence permits, and will additionally update the status of the long form agreement when possible.
We seek Safe Harbor.
© 2014 Canjex Publishing Ltd. All rights reserved.
- Published in Medical Marijuana